Skip to main content

Advertisement

SpringerLink
Log in

Supportive Therapie

Supportive therapy

  • Leitthema
  • Published:
Der Onkologe Aims and scope

Zusammenfassung

Durch Hochdosistherapie und neue Therapieverfahren konnte die Überlebenszeit von Patienten mit multiplem Myelom in den letzten Jahren deutlich verbessert werden. Besonders in Phasen der Krankheitsprogression muss jedoch mit myelomtypischen Komplikationen gerechnet werden, die das Wohlbefinden der Patienten drastisch beeinträchtigen können. Um daher die Lebensqualität der Patienten in jeder Phase der Erkrankung auf einem möglichst hohen Niveau zu erhalten, sind begleitend umfassende supportive Therapiemaßnahmen notwendig. Zu den häufigsten Komplikationen beim Myelom zählen osteolytische Knochenläsionen, die zu Schmerzen und Frakturen führen können, Hyperkalzämie, Anämie mit Fatigue-Symptomatik und Infektionen. Komplikationen im Bereich des Skelettsystems können durch Gabe von Bisphosphonaten verhindert oder verzögert werden; ebenso zählt die Gabe von Bisphosphonaten zur Standardtherapie bei Hyperkalzämie. Bestrahlung und operative Stabilisierung sind weitere Maßnahmen zur Beherrschung von Komplikationen im Bereich des Skelettsystems. Zur Therapie der Anämie stehen rekombinante Wachstumsfaktoren zur Verfügung, wobei hier Erfolge bei 60–85% der Patienten erzielt werden können. Ebenfalls in diesem Kapitel werden die Schmerztherapie sowie die Therapie und Prophylaxe von Infektionen abgehandelt.

Abstract

During the last decade, the life expectancy of patients with multiple myeloma has improved significantly, mainly due to more efficient anti-myeloma therapy. In order to preserve a high quality of life throughout the course of the disease, comprehensive supportive therapy is necessary. The most common complications occurring in patients with myeloma are osteolytic bone lesions leading to pain and fractures, hypercalcemia, anemia with fatigue, and infections. For prevention and/or therapy of these complications a variety of measures may be required, including the administration of bisphosphonates, radiation and timely operative stabilization of osteolytic lesions to prevent pathologic fractures, adequate therapy of anemia, tailored pain therapy, rapid treatment, and prophylaxis against possible infections. Treatment success increases the patients’ well-being, which is mirrored in improved quality of life.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Roux S, Meignin V, Quillard J et al. (2002) RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma. Br J Haematol 117:86–92

    Article  CAS  PubMed  Google Scholar 

  2. Lieberman I, Reinhardt MK (2003) Vertebroplasty and kyphoplasty for osteolytic vertebral collapse. Clin Orthop S176–S186

  3. McCloskey EV, MacLennan IC, Drayson MT et al. (1998) A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults. Br J Haematol 100:317–325

    Article  CAS  PubMed  Google Scholar 

  4. Berenson JR, Lichtenstein A, Porter L et al. (1996) Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 334:488–493

    Article  CAS  PubMed  Google Scholar 

  5. Berenson JR, Rosen LS, Howell A et al. (2001) Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 91:1191–1200

    Article  CAS  PubMed  Google Scholar 

  6. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62:527–534

    Article  PubMed  Google Scholar 

  7. Body JJ, Bartl R, Burckhardt P et al. (1998) Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol 16:3890–3899

    CAS  PubMed  Google Scholar 

  8. Carano A, Teitelbaum SL, Konsek JD et al. (1990) Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J Clin Invest 85:456–461

    CAS  PubMed  Google Scholar 

  9. Dammacco F, Castoldi G, Rodjer S (2001) Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol 113:172–179

    Article  CAS  PubMed  Google Scholar 

  10. Demetri GD, Kris M, Wade J et al. (1998) Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 16:3412–3425

    CAS  PubMed  Google Scholar 

  11. Ludwig H, Fritz E, Kotzmann H et al. (1990) Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 322:1693–1699

    CAS  PubMed  Google Scholar 

  12. Gabrilove JL, Cleeland CS, Livingston RB et al. (2001) Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 19:2875–2882

    CAS  PubMed  Google Scholar 

  13. Cazzola M, Beguin Y, Kloczko Jet al. (2003) Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol 122:386–393

    Article  CAS  PubMed  Google Scholar 

  14. Sunder-Plassmann G, Horl WH (1995) Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant 10:2070–2076

    CAS  PubMed  Google Scholar 

  15. Osterborg A, Brandberg Y (2003) Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 97:3125–3126

    Article  PubMed  Google Scholar 

  16. Henry D, Abels R, Larholt K (1995) Prediction of response to recombinant human erythropoietin (r-HuEPO/epoetin-alpha) therapy in cancer patients. Blood 85:1676–1678

    CAS  PubMed  Google Scholar 

  17. Cazzola M, Ponchio L, Pedrotti C et al. (1996) Prediction of response to recombinant human erythropoietin (rHuEpo) in anemia of malignancy. Haematologica 81:434–441

    CAS  PubMed  Google Scholar 

  18. Salutari P, Sica S, Laurenti L et al. (1998) Incidence of sepsis after peripheral blood progenitor cells transplantation: analysis of 86 consecutive hemato oncological patients. Leuk Lymphoma 30:193–197

    CAS  PubMed  Google Scholar 

  19. Oken MM, Pomeroy C, Weisdorf D, Bennett JM (1996) Prophylactic antibiotics for the prevention of early infection in multiple myeloma. Am J Med 100:624–628

    Article  CAS  PubMed  Google Scholar 

  20. Chapel HM, Lee M, Hargreaves R et al. (1994) Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma. Lancet 343:1059–1063

    Article  CAS  PubMed  Google Scholar 

  21. Aviles A, Guzman R, Garcia EL et al. (1996) Results of a randomized trial of granulocyte colony-stimulating factor in patients with infection and severe granulocytopenia. Anticancer Drugs 7:392–397

    CAS  PubMed  Google Scholar 

  22. Silvestris F, Romito A, Fanelli P, Vacca A, Dammacco F (1995) Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma. Ann Hematol 70:313–318

    Article  CAS  PubMed  Google Scholar 

  23. Garton JP, Gertz MA, Witzig TE et al. (1995) Epoetin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled, double-blind trial. Arch Intern Med 155:2069–2074

    Article  CAS  PubMed  Google Scholar 

  24. Cazzola M, Messinger D, Battistel V et al. (1995) Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin’s lymphoma: dose finding and identification of predictors of response. Blood 86:4446–4453

    CAS  PubMed  Google Scholar 

  25. Osterborg A, Boogaerts MA, Cimino R et al. (1996) Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin’s lymphoma—a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin’s Lymphoma. Blood 87:2675–2682

    CAS  PubMed  Google Scholar 

  26. Dammacco F, Silvestris F, Castoldi GL et al. (1998) The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapy. Int J Clin Lab Res 28:127–134

    Article  CAS  PubMed  Google Scholar 

  27. Osterborg A, Brandberg Y, Molostova V et al. (2002) Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies. J Clin Oncol 20:2486–2494

    Article  CAS  PubMed  Google Scholar 

  28. Hedenus M, Adriansson M, San Miguel J et al. (2003) Darbepoetin Alfa 20000161 Study Group. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 122 (3):394–403

    Article  CAS  PubMed  Google Scholar 

Download references

Interessenkonflikt:

Der korrespondierende Autor weist auf eine Verbindung mit folgender Firma/Firmen hin: Amgen, Hoffmann-La Roche, Janssen-Cilag

Author information

Authors and Affiliations

  1. Medizinische Abteilung mit Onkologie, Wilhelminenspital, Wien

    N. Zojer, K. Strasser-Weippl &  H. Ludwig

  2. Medizinische Abteilung mit Onkologie, Wilhelminenspital, Wien

    H. Ludwig

Authors
  1. N. Zojer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Strasser-Weippl
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Ludwig
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. Ludwig.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zojer, N., Strasser-Weippl, K. & Ludwig, H. Supportive Therapie. Onkologe 10, 843–851 (2004). https://doi.org/10.1007/s00761-004-0741-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-004-0741-0

Schüsselwörter

Keywords

Search

Navigation